Howard E. Gendelman

From Wikipedia, the free encyclopedia

Howard E. Gendelman (born March 18, 1954) is an American physician-scientist whose research intersects the disciplines of neuroimmunology, pharmacology, and infectious diseases. Gendelman was born in Philadelphia, Pennsylvania. He is renowned for his research in harnessing immune responses for therapeutic gain in HIV/AIDS and Neurodegenerative disease. He is an author, editor, educator, and mentor.

Since 2004, he has held the position of Margaret R. Larson Professor of infectious diseases and internal medicine at the University of Nebraska Medical Center (UNMC) in Omaha. He is the founding chair of the Department of Pharmacology and Experimental Neuroscience, director of the Center for Neurodegenerative Disorders, and the head of the Carol Swarts MD Neuroscience Laboratory.[1]

Gendelman possesses an H-index of 113,[2] authored more than 550 peer-reviewed publications, edited 17 books and monographs, is the recipient of numerous national and international research and mentoring awards, and holds 38 patents. He was the founding editor-in-chief of the Journal of Neuroimmune Pharmacology[3] (2004–2021) and currently leads the journal NeuroImmune Pharmacology and Therapeutics (2022–present).

He is married with three children and seven grandchildren.[4]

Early life and education[]

Gendelman graduated with a bachelor's degree in Natural Sciences and Russian Studies from Muhlenberg College (1971-1975). He completed his doctorate of medicine at the Pennsylvania State University-Hershey Medical Center (1975-1979) where he held Research Associate and Instructor positions. Gendelman then completed a residency in Internal medicine at Montefiore Hospital, Albert Einstein College of Medicine (1979-1982), and he was a Clinical and Research Fellow in Neurology and Infectious Diseases at the Johns Hopkins University Medical Center (1982-1985).

Career[]

Early career[]

Gendelman worked at the National Institute of Allergy and Infectious Diseases during the height of the HIV/AIDS Pandemic.[5] Gendelman also occupied senior faculty and research positions at the Johns Hopkins Medical Institutions, the Uniformed Services University of the Health Sciences Center, the Walter Reed Army Institute of Research, and the Henry M. Jackson Foundation for the Advancement in Military Medicine before joining the faculty of UNMC in March 1993. He retired from the US Army with the rank of Lieutenant Colonel. He established the Center for Neurovirology and Neurodegenerative Disorders at UNMC in 1997,[6] which evolved into UNMC's current Department of Pharmacology and Experimental Neuroscience in 2004.[7]

Mononuclear phacocytes and neurodegenerative disease[]

Gendelman's research[2] explores the role of mononuclear phagocytes (monocytes, macrophages, microglia, and dendritic cells) as viral reservoirs, perpetrators of disease, and depots for nanoformulated drug delivery. His work was foundational to building a field of investigation focused on lentiviral pathogenesis, diagnostics, and therapeutics. These advancements in immune transformation have led to new and effective management of neurodegenerative disease progression. Gendelman and his research team were amongst the first to develop laboratory assays for establishing viral tropism for mononuclear phagocytes, and they were the first to demonstrate that infected and immune activated mononuclear phagocytes release viral and cellular toxins that damage the nervous system.[8][9][10]

HIV research contributions[]

Gendelman's group was among the first to reverse HIV-dementia in an infected person using combination antiretroviral therapy (cART), and they developed scores of rodent models to mimic HIV/AIDS end-organ disease.[11][12][13] He coined the term long-acting slow effective release ART (LASER ART). These works led to polymer discovery, targeted drug delivery to viral reservoirs, and reduction of residual virus in lymphoid organs. His research group was also the first to combine HIV reservoir-targeted LASER ART and CRISPR-Cas9 to eliminate chronic viral infection from infected animals. This curative approach (published in Nature Communications, 2019) received considerable attention in establishing a novel translational pathway for HIV eradication.[14][15][16] This work followed the first ultra-long acting nanocrystal prodrug and the world's first HIV vaccine mimetic[17][18] (in Nature Materials, 2020). His work with cell-based drug delivery born out of nanoparticle-mononuclear phagocyte interactions has inspired broad pharmaceutical interest; in turn, Gendelman led the establishment of the Nebraska Nanomedicine Production Plant,[19] a biotechnology good manufacturing practices (cGMP) initiative, to position research for clinical translation in the development of long acting nanoformulated ART at UNMC. He also co-founded Exavir Therapeutics, Inc.,[20] a biotechnology company developing therapies towards and cure for HIV/AIDS.

Parkinson's Disease research contributions[]

Gendelman was the first to pharmacologically transform effector into regulatory T cells to halt the progression of Parkinson's disease.[21][22] Phase II investigation began in early 2021 after successful phase I investigations[23]

Scientific community leadership[]

Gendelman has written or edited 17 books and monographs (including multiple editions of the textbooks The Neurology of AIDS[24] and Neuroimmune Pharmacology[25]). He has mentored graduate students, postdoctoral fellows, and early career faculty. He trained more than 70 students, fellows, and junior faculties who are now Deans, departmental chairpersons, professors and leaders in the pharmaceutical industry and in healthcare. He was the founding Editor-in-Chief of the Journal of Neuroimmune Pharmacology.[3] He serves on fifteen editorial boards and scientific review committees at state, national, and international levels. He has given more than 200 invited scientific seminars and symposia, and he has provided numerous lectures to the general public[1]

Awards and honors[]

Research recognitions:[26][]

  • Lifetime Achievement Award, Contribution to the Advancement of the Mission of the Society on NeuroImmune Pharmacology, 2017[27]
  • Pioneer in NeuroVirology, International Society for NeuroVirology, 2016
  • UNMC Outstanding Faculty Mentor of the Year, 2014
  • UNMC Innovator of the Year, 2013
  • Herman Friedman Founders NeuroImmune Pharmacology Society Prize, 2013
  • University of Nebraska Outstanding Research and Creative Activity (ORCA) Award, 2012
  • UNMC Scientist Laureate and Distinguished Scientist, 2008
  • Wybran NeuroImmune Pharmacology Prize, 2007
  • Internal Medicine Research Career Excellence Award, UNMC, Department of Internal Medicine, 2003
  • Top Physicians, Consumer's Research Council of America, 2003
  • Jacob Javits Neuroscience Research Award, National Institute of Neurological Disorders and Stroke, NIH, NINDS, 2001
  • J. William Fulbright Research Scholar, Weizmann Institute of Science, Rehovot, Israel, 2000
  • Pennsylvania State University "Distinguished Alumnus" Alumni Fellow Pennsylvania State University-Milton S. Hershey Medical Center, 1999
  • UNMC Special Achievement Award-1999 and 2000
  • Pennsylvania State University-Hershey Medical Center, 1999 Distinguished Alumnus

Omaha community honors[]

  • Humanitarian of the Year Award, Jewish Federation of Omaha, 2018.[4]

References[]

  1. ^ a b "Howard E. Gendelman, MD | Pharmacology | University of Nebraska Medical Center". www.unmc.edu. Retrieved 2021-12-16.
  2. ^ a b "Howard E. Gendelman". scholar.google.com. Retrieved 2021-12-16.
  3. ^ a b "Journal of Neuroimmune Pharmacology". Springer. Retrieved 2021-12-16.
  4. ^ a b Utesch, Margie (2018-07-03). "Humanitarian of the Year". The Jewish Community Center of Omaha. Retrieved 2021-12-16.
  5. ^ "Potential new HIV treatment developed at UNMC". KMTV. 2020-04-29. Retrieved 2021-12-16.
  6. ^ "Front Line (2009)" (PDF). University of Nebraska Medical Center, Department of Pharmacology and Experimental Neuroscience. Retrieved 2022-01-25.
  7. ^ "About Us". University of Nebraska Medical Center, Department of Pharmacology and Experimental Neuroscience. Retrieved 2022-01-25.
  8. ^ Adachi, A; Gendelman, H E; Koenig, S; Folks, T; Willey, R; Rabson, A; Martin, M A (August 1986). "Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone". Journal of Virology. 59 (2): 284–291. doi:10.1128/jvi.59.2.284-291.1986. ISSN 0022-538X. PMC 253077. PMID 3016298. S2CID 12551511.
  9. ^ Koenig, Scott; Gendelman, Howard E.; Orenstein, Jan M.; Dal Canto, Mauro C.; Pezeshkpour, Gholam H.; Yungbluth, Margaret; Janotta, Frank; Aksamit, Allen; Martin, Malcolm A.; Fauci, Anthony S. (1986-09-05). "Detection of AIDS Virus in Macrophages in Brain Tissue from AIDS Patients with Encephalopathy". Science. 233 (4768): 1089–1093. Bibcode:1986Sci...233.1089K. doi:10.1126/science.3016903. ISSN 0036-8075. PMID 3016903.
  10. ^ Gendelman, H. E.; Narayan, O.; Molineaux, S.; Clements, J. E.; Ghotbi, Z. (October 1985). "Slow, persistent replication of lentiviruses: role of tissue macrophages and macrophage precursors in bone marrow". Proceedings of the National Academy of Sciences of the United States of America. 82 (20): 7086–7090. Bibcode:1985PNAS...82.7086G. doi:10.1073/pnas.82.20.7086. ISSN 0027-8424. PMC 391315. PMID 2996004.
  11. ^ Gendelman, Howard E.; Zheng, Jialin; Coulter, Cynthia L.; Ghorpade, Anuja; Che, Myhanh; Thylin, Michael; Rubocki, Ronald; Persidsky, Yuri; Hahn, Francis; Reinhard, Jr., John; Swindells, Susan (October 1998). "Suppression of Inflammatory Neurotoxins by Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus‐Associated Dementia". The Journal of Infectious Diseases. 178 (4): 1000–1007. doi:10.1086/515693. ISSN 0022-1899. PMID 9806027.
  12. ^ Spellman, Lisa; August 09, UNMC public relations |; 2019 (2019-08-09). "Science Cafe explores possibility of HIV cure". University of Nebraska Medical Center. Retrieved 2021-12-16.{{cite web}}: CS1 maint: numeric names: authors list (link)
  13. ^ Gendelman, Howard E. (2012). The neurology of AIDS. Oxford University Press. ISBN 978-0-19-539934-9. OCLC 828615707.
  14. ^ "In a first, scientists eliminate HIV from an animal's genome". www.cbsnews.com. Retrieved 2021-12-17.
  15. ^ Yancey-Bragg, N'dea. "Researchers have eliminated HIV in mice for the first time. Is a cure for humans next?". USA TODAY. Retrieved 2021-12-17.
  16. ^ Dash, Prasanta K.; Kaminski, Rafal; Bella, Ramona; Su, Hang; Mathews, Saumi; Ahooyi, Taha M.; Chen, Chen; Mancuso, Pietro; Sariyer, Rahsan; Ferrante, Pasquale; Donadoni, Martina (December 2019). "Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice". Nature Communications. 10 (1): 2753. Bibcode:2019NatCo..10.2753D. doi:10.1038/s41467-019-10366-y. ISSN 2041-1723. PMC 6606613. PMID 31266936.
  17. ^ Kulkarni, Tanmay A.; Bade, Aditya N.; Sillman, Brady; Shetty, Bhagya Laxmi Dyavar; Wojtkiewicz, Melinda S.; Gautam, Nagsen; Hilaire, James R.; Sravanam, Sruthi; Szlachetka, Adam; Lamberty, Benjamin G.; Morsey, Brenda M. (August 2020). "A year-long extended release nanoformulated cabotegravir prodrug". Nature Materials. 19 (8): 910–920. Bibcode:2020NatMa..19..910K. doi:10.1038/s41563-020-0674-z. ISSN 1476-1122. PMC 7384935. PMID 32341511.
  18. ^ Soriano, Vicente; Barreiro, Pablo; de Mendoza, Carmen (August 2020). "Long-acting antiretroviral therapy". Nature Materials. 19 (8): 826–827. Bibcode:2020NatMa..19..826S. doi:10.1038/s41563-020-0731-7. ISSN 1476-4660. PMID 32704135. S2CID 220721631.
  19. ^ "Nebraska Nanomedicine Production Plant | Pharmacology | University of Nebraska Medical Center". www.unmc.edu. Retrieved 2021-12-16.
  20. ^ "Exavir Therapeutics". exavirtherapeutics.com. 2021-02-14. Retrieved 2021-12-16.
  21. ^ Benner, Eric J.; Mosley, R. Lee; Destache, Chris J.; Lewis, Travis B.; Jackson-Lewis, Vernice; Gorantla, Santhi; Nemachek, Craig; Green, Steven R.; Przedborski, Serge; Gendelman, Howard E. (2004-06-22). "Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease". Proceedings of the National Academy of Sciences of the United States of America. 101 (25): 9435–9440. Bibcode:2004PNAS..101.9435B. doi:10.1073/pnas.0400569101. ISSN 0027-8424. PMC 438994. PMID 15197276.
  22. ^ Gendelman, Howard E.; Zhang, Yuning; Santamaria, Pamela; Olson, Katherine E.; Schutt, Charles R.; Bhatti, Danish; Shetty, Bhagya Laxmi Dyavar; Lu, Yaman; Estes, Katherine A.; Standaert, David G.; Heinrichs-Graham, Elizabeth (2017-03-23). "Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial". NPJ Parkinson's Disease. 3 (1): 10. doi:10.1038/s41531-017-0013-5. ISSN 2373-8057. PMC 5445595. PMID 28649610.
  23. ^ Olson, Katherine E.; Namminga, Krista L.; Lu, Yaman; Schwab, Aaron D.; Thurston, Mackenzie J.; Abdelmoaty, Mai M.; Kumar, Vikas; Wojtkiewicz, Melinda; Obaro, Helen; Santamaria, Pamela; Mosley, R. Lee (2021-05-01). "Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's disease". EBioMedicine. 67: 103380. doi:10.1016/j.ebiom.2021.103380. ISSN 2352-3964. PMC 8138485. PMID 34000620.
  24. ^ Gendelman, Howard E; Grant, Igor; Everall, Ian Paul; Fox, Howard S; Gelbard, Harris A; Lipton, Stuart A; Swindells, Susan, eds. (2012). The Neurology of AIDS. Oxford University Press. doi:10.1093/med/9780195399349.001.0001. ISBN 978-0-19-996519-9.
  25. ^ Ikezu, Tsuneya; Gendelman, Howard E., eds. (2017). Neuroimmune Pharmacology. doi:10.1007/978-3-319-44022-4. ISBN 978-3-319-44020-0.
  26. ^ "Howard E. Gendelman, MD, Biographical Information | Pharmacology | University of Nebraska Medical Center". www.unmc.edu. Retrieved 2021-12-16.
  27. ^ "SNIP - Society on NeuroImmune Pharmacology". s-nip.org. Retrieved 2021-12-16.
Retrieved from ""